Literature DB >> 2556795

Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.

R P Viscidi1, K Mayur, H M Lederman, A D Frankel.   

Abstract

The purified human immunodeficiency virus type-l (HIV-l) Tat protein inhibited lymphocyte proliferation induced by tetanus toxoid or Candida antigens by 66 to 97% at nanomolar concentrations of Tat. In contrast, Tat did not cause a significant reduction of lymphocyte proliferation in response to mitogens such as phytohemagglutinin or pokeweed mitogen. Inhibition was blocked by oxidation of the cysteine-rich region of Tat or by incubation with an antibody to Tat before the assay. A synthetic Tat peptide (residues 1 to 58) also inhibited antigen-stimulated proliferation. Experiments with H9 and U937 cell lines showed that Tat can easily enter both lymphocytes and monocytes. The specific inhibition of antigen-induced lymphocyte proliferation by Tat mimics the effect seen with lymphocytes from HIV-infected individuals and suggests that Tat might directly contribute to the immunosuppression associated with HIV infection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556795     DOI: 10.1126/science.2556795

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  93 in total

1.  Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge.

Authors:  S S Cohen; C Li; L Ding; Y Cao; A B Pardee; E M Shevach; D I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.

Authors:  R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

3.  Tat-neutralizing antibodies in vaccinated macaques.

Authors:  Ilia Tikhonov; Tracy J Ruckwardt; Glen S Hatfield; C David Pauza
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  Activation of expression of genes coding for extracellular matrix proteins in Tat-producing glioblastoma cells.

Authors:  J P Taylor; C Cupp; A Diaz; M Chowdhury; K Khalili; S A Jimenez; S Amini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

5.  Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.

Authors:  Emmanuel Moreau; Johan Hoebeke; Daniel Zagury; Sylviane Muller; Claude Desgranges
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

6.  The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation.

Authors:  M B Feinberg; D Baltimore; A D Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

7.  Mycobacterium avium infection in HIV-1-infected subjects increases monokine secretion and is associated with enhanced viral load and diminished immune response to viral antigens.

Authors:  M Denis; E Ghadirian
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Central nervous system-derived cells express a kappa B-binding activity that enhances human immunodeficiency virus type 1 transcription in vitro and facilitates TAR-independent transactivation by Tat.

Authors:  J P Taylor; R J Pomerantz; G V Raj; F Kashanchi; J N Brady; S Amini; K Khalili
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  Dendritic cells infected with vpr-positive human immunodeficiency virus type 1 induce CD8+ T-cell apoptosis via upregulation of tumor necrosis factor alpha.

Authors:  Biswanath Majumder; Narasimhan J Venkatachari; Elizabeth A Schafer; Michelle L Janket; Velpandi Ayyavoo
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

10.  Modified antisense oligodeoxynucleotides against the splice acceptor site of tat do not inhibit in vitro hematopoietic colony growth in HIV-positive patients.

Authors:  R G Geissler; J Muth; A Maurer; U Mentzel; M Mag; J W Engels; D Hoelzer; A Ganser
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.